Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Sunday Times best places to work list 2026: 22 South West companies named

Published

on

Business Live

All the businesses included are headquartered in the West Country

The team at Goughs Solicitors which is headquartered in Wiltshire

The team at Goughs Solicitors which is headquartered in Wiltshire(Image: Goughs)

A South West brewery group, law firm and free range egg producer have been named among the best places to work in the UK. The annual rankings are compiled by the Sunday Times and its research partner – employee experience platform WorkL – and recognise the country’s top employers.

There were 22 South West companies included for 2026, with businesses across a range of industries such as hospitality, technology, legal, financial services and education.

The list – now in its fourth year – highlights the best small, medium, big and very big organisations for workplace culture – from those with hybrid working policies and career development opportunities to unique initiatives that support staff.

Inclusion is determined by an independent survey that covers six aspects of employee engagement, such as wellbeing, empowerment and job satisfaction, and is voted for by a company’s staff.

Advertisement

West Country pub operator and brewer Butcombe was recognised for the second year running. The Wrington-based group – formerly known as Liberation – said its inclusion reflected “the environment we have worked hard to create”.

Jonathan Lawson, chief executive of Butcombe Group, said: “At the heart of our success is the dedication and collaboration shown by our people every day, whether they are welcoming guests, creating memorable moments, or supporting one another behind the scenes.

“In what continues to be a challenging environment for the hospitality sector, their commitment to delivering exceptional experiences for our customers continues to make a real difference.”

Wiltshire-based law firm Goughs Solicitors, which employs some 130 staff across seven offices, was included for the third year in a row.

Advertisement

“We are incredibly proud to receive this recognition from The Sunday Times,” said Matthew Drew, managing partner at Goughs Solicitors. “To be acknowledged consistently in this way is a real reflection of the firm’s culture and the values that guide us.

“As our people are at the centre of everything we do, we strive to creating a workplace where colleagues feel valued, supported, and empowered to achieve their full potential, both professionally and personally.”

Elsewhere, Cheltenham-based business transformation firm Commercial also made the list. The company employs nearly 300 people and generates an annual turnover of around £98m.

Recent employee-focused developments include the refurbishment of its headquarters, with workspaces tailored to support neurodiverse staff. It also has a multi-faith room and dedicated spaces for employees with children or dogs.

Advertisement
Commercial: Back row: Dean Chester, Katie Lund, Jay Colling, Zaneta Rydzewska, Larrisa Castro. Front Row:  Guy Ward, Craig Baldwin, Jenny Hodgson (People & Culture Director), Simone Hindmarch (Co-Founder and MD), Craig Tomes, Jordan Thomas

Commercial: Back row: Dean Chester, Katie Lund, Jay Colling, Zaneta Rydzewska, Larrisa Castro. Front Row: Guy Ward, Craig Baldwin, Jenny Hodgson (People & Culture Director), Simone Hindmarch (Co-Founder and MD), Craig Tomes, Jordan Thomas(Image: Copyright © 2026 Fred van Leeuwen)

Simone Hindmarch, co-founder and managing director of Commercial, said the recognition was “especially meaningful” because it reflected the culture the business had worked to build over more than three decades.

“This means a huge amount to us because it’s based on what our people think and feel about working at Commercial. Right from the start, we wanted to create a company where people genuinely wanted to come to work, felt connected to the business and each other, and knew their voice mattered,” she said. “To have that recognised in this way is incredibly special.”

In other parts of the South West, Cornwall-based egg producer St Ewe Free Range Eggs also made the list, along with Swindon marketing agency Mole Digital and Exeter construction group Coreus.

Zoe Thomas, editor of The Sunday Times Best Places to Work, added: “In an evolving world of work Britain’s leading employers are helping staff forge careers that count today – and in the future. In turn, the Best Places to Work have the resilience to weather the current economic storms baked in, thanks to engaged workers who go above and beyond with a smile.

Advertisement

“Our winning employers span sizes and sectors – from tiny charities and specialist law firms, to multinational fast-food chains and utility giants, and everywhere in between. The thread joining them is the belief that a happy workforce is a stepping stone to better performance, faster growth, and bigger profits.”

The South West companies on the Sunday Times best places to work list 2026

In alphabetical order…

  1. Awdry Law, Legal Services, Devizes, Wiltshire
  2. Butcombe Group, Hospitality, Bristol
  3. Commercial, Business and Management Services, Cheltenham, Gloucestershire
  4. Compass CHC, Legal Services, Barnstaple, Devon
  5. Coreus Group, Construction and Building Materials, Exeter
  6. Family Adventures Group, Education and Research, Weston-super-Mare, Somerset
  7. Goughs Solicitors, Legal Services, Melksham, Wiltshire
  8. Hall & Woodhouse, Hospitality, Blandford St Mary, Dorset
  9. InterWorks, Technology, Christchurch, Dorset
  10. iplicit, Technology, Bournemouth
  11. Joint Operations, Health and Social Care, Royal Wootton Bassett, Wiltshire
  12. Mole Digital, Marketing and Advertising, Swindon
  13. Oculus Legal Group, Business and Management Services, Bristol
  14. Paragon Skills, Education and Research, Bournemouth
  15. Parmenion, Financial Services, Bristol
  16. Rappor, Construction and Building Materials, Cheltenham
  17. Shaping Lives, Education and Research, Bournemouth
  18. St Ewe Free Range Eggs, Manufacturing of Consumer Goods, Truro, Cornwall
  19. Taxi Studio, Architecture & Design, Bristol
  20. The Cinnamon Trust, Non-Profit Organisations and Charities, Hayle, Cornwall
  21. Xpedite, Defence, Bath
  22. Zestec Renewable Energy, Energy and Utilities, Bournemouth
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Fisher & Paykel Healthcare Shares Surge 9% on Strong Full-Year Results and Upgraded Outlook

Published

on

Fisher & Paykel Healthcare Shares Surge 9% on Strong Full-Year

SYDNEY — Shares in Fisher & Paykel Healthcare Corporation Ltd jumped more than 9% on Tuesday after the New Zealand medical device maker reported robust full-year results and reaffirmed confidence in its growth trajectory amid rising global demand for respiratory care products.

The stock climbed $2.52, or 9.15%, to close at $30.05 on the ASX and NZX, marking one of its strongest single-day gains in recent months. The rally reflected investor enthusiasm for the company’s performance in the year ended March 31, 2026, as well as optimism about its position in the expanding healthcare technology sector.

Fisher & Paykel, a leader in humidified respiratory care, sleep apnea treatment and surgical products, has benefited from sustained demand for its equipment in hospitals and home care settings worldwide. The company’s products, including high-flow nasal cannula systems and CPAP devices, have seen particular strength in North America and Europe.

Analysts highlighted the company’s ability to deliver margin expansion despite supply chain challenges and currency fluctuations. The results come after the company upgraded its fiscal 2026 guidance earlier in the year, projecting operating revenue of approximately NZ$2.30 billion and net profit after tax between NZ$450 million and NZ$470 million.

Advertisement

The strong share price reaction underscores Fisher & Paykel’s status as a market darling on the NZX and ASX. As one of New Zealand’s largest listed companies by market capitalization, its performance carries significant weight for the broader market and superannuation funds with heavy exposure to the healthcare sector.

Investors appear particularly encouraged by the company’s consistent innovation pipeline and growing presence in emerging markets. Fisher & Paykel has expanded its manufacturing footprint and invested in research and development to maintain its technological edge in non-invasive ventilation and airway management solutions.

The medical device sector has faced headwinds from inflation, logistics costs and regulatory pressures in recent years. Fisher & Paykel’s ability to navigate these challenges while delivering growth has set it apart from peers and supported premium valuations.

Company executives are scheduled to host an investor briefing following the results release, providing further details on strategic priorities for the coming year. Key focus areas are expected to include continued penetration in the hospital market, expansion of its homecare portfolio and opportunities in digital health integration.

Advertisement

The surge also comes against a backdrop of broader market caution, with many healthcare stocks facing pressure from potential policy changes and reimbursement uncertainties in key markets like the United States. Fisher & Paykel’s resilience highlights the defensive qualities of its recurring revenue business model.

Longer-term tailwinds for the company include aging populations in developed markets, rising prevalence of respiratory conditions linked to pollution and obesity, and increasing adoption of home-based care models post-pandemic. These structural trends support Fisher & Paykel’s medium-term growth targets.

Analysts have generally maintained positive outlooks on the stock. JPMorgan initiated coverage with an Overweight rating and a price target of NZ$37.50 earlier in 2026, citing strong organic growth potential and margin improvement opportunities. Other brokers have also raised targets following recent guidance upgrades.

The company’s focus on sustainability and product innovation has resonated with institutional investors. Recent product launches in high-flow therapy and advanced humidification systems have been well received by clinicians, supporting market share gains.

Advertisement

Geographically, North America remains the largest contributor to revenue, followed by Europe and Asia-Pacific. The company continues to invest in localized manufacturing and distribution to mitigate currency risks and improve service levels for customers.

Fisher & Paykel’s success reflects broader shifts in healthcare delivery. The emphasis on non-invasive solutions that reduce hospital stays aligns with cost-control pressures faced by health systems globally. Its products have played important roles in managing conditions ranging from sleep apnea to chronic obstructive pulmonary disease.

For retail investors on the ASX and NZX, the stock offers exposure to a high-quality growth company with strong cash flow characteristics. Dividend payouts have been attractive, providing income alongside capital appreciation potential.

The 9% gain on Tuesday helped recover some of the ground lost earlier in the year when the stock faced pressure from broader market rotation out of growth names. At current levels, the shares trade at a premium valuation, reflecting expectations of continued double-digit earnings growth.

Advertisement

Market watchers will closely monitor the upcoming investor briefing for any updates on capital allocation, including potential acquisitions or increased shareholder returns. The company has a track record of disciplined investment while maintaining a healthy balance sheet.

The rally also highlights the appeal of New Zealand-listed healthcare names amid global economic uncertainty. With stable governance, strong intellectual property and diversified revenue streams, Fisher & Paykel stands out as a quality compounder in the eyes of many fund managers.

Looking ahead, the company faces typical industry risks including competition, regulatory changes and currency volatility. However, its established brand, clinical evidence base and innovation track record provide a solid foundation for sustained performance.

Tuesday’s trading volume was elevated as investors repositioned portfolios following the results. The positive reaction suggests broad market agreement that Fisher & Paykel is well-placed to capitalize on long-term healthcare trends.

Advertisement

As one of Australasia’s most valuable healthcare companies, its performance influences sentiment toward the wider sector. The strong result may encourage renewed interest in other medical device and pharmaceutical names on both sides of the Tasman.

For the coming financial year, analysts expect continued revenue growth in the high single digits to low double digits, supported by new product cycles and geographic expansion. Margin improvement is also anticipated as supply chain normalization continues.

The Fisher & Paykel story exemplifies successful Kiwi innovation on the global stage. From humble beginnings in respiratory humidification, the company has grown into an international player with products used in thousands of hospitals worldwide.

Tuesday’s share price surge provides fresh momentum as the company enters its new financial year. With a clear strategy and strong execution, Fisher & Paykel Healthcare appears positioned to deliver further value for shareholders in the years ahead.

Advertisement
Continue Reading

Business

John Hancock Bond Fund Q1 2026 Commentary

Published

on

Voya High Yield Bond Fund Q4 2025 Commentary

A company of Manulife Investment Management, John Hancock Investment Management serves investors through a unique multimanager approach, complementing our extensive in-house capabilities with an unrivaled network of specialized asset managers, backed by some of the most rigorous investment oversight in the industry. The result is a diverse lineup of time-tested investments from a premier asset manager with a heritage of financial stewardship. Note: This account is not managed or monitored by John Hancock Investment Management, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use John Hancock Investment Management’s official channels.

Continue Reading

Business

NRW books contracts worth $120m

Published

on

NRW books contracts worth $120m

For the second time in just over a month, NRW’s subsidiary Fredon has booked a sizeable suite of contracts.

Continue Reading

Business

Flight Centre Travel Group Limited (FGETF) Analyst/Investor Day – Slideshow

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Flight Centre Travel Group Limited (FGETF) Analyst/Investor Day – Slideshow

Continue Reading

Business

Navy chief's warning over sea lanes, submarine politicisation

Published

on

Navy chief's warning over sea lanes, submarine politicisation

The head of Australia’s Navy, who will soon lead Australia’s defence force more broadly, says access to global sea lanes has become an existential crisis for the nation.

Continue Reading

Business

Bank holiday sun boosts South West tourism

Published

on

Bank holiday sun boosts South West tourism

Business owners in Devon and Cornwall describe how “the sun just brings everybody out”.

Continue Reading

Business

BOJ’s new trend gauge shows inflation exceeding target

Published

on

BOJ’s new trend gauge shows inflation exceeding target


BOJ’s new trend gauge shows inflation exceeding target

Continue Reading

Business

MinRes, Ganfeng invest $490m in Mt Marion underground lithium expansion

Published

on

MinRes, Ganfeng invest $490m in Mt Marion underground lithium expansion

Mineral Resources and its JV partner are investing $490 million in an underground expansion of its Mt Marion lithium mine, a move it expects will pay off in less than a year.

Continue Reading

Business

ECB should raise rates in June, even if Iran peace deal is struck, Schnabel says

Published

on

ECB should raise rates in June, even if Iran peace deal is struck, Schnabel says


ECB should raise rates in June, even if Iran peace deal is struck, Schnabel says

Continue Reading

Business

TACHI-S Co., Ltd. 2026 Q4 – Results – Earnings Call Presentation (OTCMKTS:TCISF) 2026-05-26

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Trending

Copyright © 2025